|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacologically inhibiting this pathway substantially delays progression, and it improves survival of murine leukemia through stabilizing wild-type MLL protein, which displaces the MLL chimera from some of its target genes and, therefore, relieves the cellular oncogenic addiction to MLL chimeras.
|
28065413 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed lineage leukemia is characterized by the presence of MLL fusion proteins that are the result of chromosomal translocations affecting the MLL gene at 11q23.
|
19535349 |
2009 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To study molecular mechanisms, we cloned and characterized the MLL promoter region and used small interfering RNA for MLL and specific inhibitors for signal transduction pathways.
|
19318494 |
2009 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
We established an acute myeloid leukemia (AML) model by overexpressing the human mixed-lineage leukemia-AF9 (MLL-AF9) fusion gene in mouse hematopoietic cells that carry Yamanaka factors under the control of doxycycline (Dox).
|
24150221 |
2014 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mixed lineage leukemia (MLL) gene undergoes chromosomal translocations, resulting in the formation of oncogenic MLL fusion proteins (MLL-FPs).
|
20159607 |
2010 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This targeting strategy does not affect other mixed-lineage leukemia (MLL) family histone methyltransferases (HMTs), revealing a unique regulatory feature for the MLL1 complex.
|
24389101 |
2014 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Upon androgen stimulation, AR recruits the Protein kinase N1 (PKN1), which phosphorylates histone H3 at threonine 11, with subsequent recruitment of tryptophan, aspartic acid (WD) repeat-containing protein 5 (WDR5) and the su(var)3-9, enhancer of zeste, trithorax/mixed-lineage leukemia (SET1/MLL) histone methyltransferase complex to promote AR target gene activation and prostate cancer cell growth.
|
27268279 |
2016 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (<i>MLL</i>) gene rearrangements (<i>MLL-r</i>) resulting from 11q23 translocations.
|
29724899 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL5, assigned as KMT2E on the basis of its SET domain homology, was initially categorized under MLL (KMT2) family together with other six SET methyltransferase domain proteins (KMT2A-2D and 2F-2G).
|
28188343 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal rearrangements of the mixed lineage leukemia (MLL/KMT2A) gene leading to oncogenic MLL-fusion proteins occur in ~10% of acute leukemias and are associated with poor clinical outcomes, emphasizing the need for new treatment modalities.
|
27840424 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we discuss the potential molecular role of the PAFc in transcriptional dysregulation of MLL target genes and the interplay between PAFc and MLL-rearranged oncoproteins in leukemogenesis.
|
21037944 |
2010 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address this, we generated a mouse model in which the mixed-lineage leukemia/eleven-nineteen-leukemia (MLL-ENL) transcription factor can be conditionally activated in any cell type.
|
25456127 |
2014 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The same differences concerning dCK and hENT1 mRNA expression were observed between MLL gene-rearranged (n = 14) and germ line MLL cases (n = 25).
|
12406912 |
2003 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rearrangement of the mixed lineage leukemia (MLL; also known as lysine methyltransferase 2A) gene is a recurrent genomic aberration in acute myeloid leukemia (AML).
|
31789407 |
2020 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
We applied our methods to five cancerous gene expression datasets: leukemia (acute lymphoblastic leukemia [ALL] vs. acute myeloid leukemia [AML]), lung cancer, prostate cancer, breast cancer, and leukemia (ALL vs. mixed-lineage leukemia [MLL] vs. AML).
|
19874631 |
2009 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, DOT1L is believed to be involved in the development of MLL-rearranged leukemia driven by the MLL (mixed-lineage leukemia) fusion proteins, which thus to be a crucial target for leukemia therapy.
|
29534934 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features.
|
30143999 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MLL protein complex has been shown to interact with the androgen receptor via the MLL-menin subunit, thus promoting gene activation.
|
27705736 |
2016 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, ASH1L facilitates recruitment of LEDGF and wild-type MLL proteins to chromatin at key leukemia target genes and is a crucial regulator of MLL-dependent transcription and leukemic transformation.
|
27154821 |
2016 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) lead to recruitment of DOT1L, to a multi-protein complex resulting in aberrant methylation of histone H3 lysine 79 at MLL target genes, and ultimately enhanced expression of critical genes for hematopoietic differentiation, including HOXA9 and MEIS1, and as such defines the established mechanism for leukemogenesis in MLL-rearrangement (MLL-r) leukemias.
|
28229434 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The possible involvement of germline mutation of the ataxia telangiectasia mutated (ATM) gene in childhood acute leukemia with mixed lineage leukemia (MLL) gene rearrangement (MLL(+)) was investigated.
|
12511424 |
2003 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the incidence of the mixed lineage leukemia (MLL) gene rearrangements in acute myeloid leukemia (AML) without cytogenetically-detected 11q23 abnormalities, we screened 64 cases of AML at diagnosis for MLL rearrangement by FISH.
|
11911106 |
2002 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taspase1, a highly conserved threonine protease, cleaves nuclear transcriptional regulators mixed-lineage leukemia (MLL, MLL1), MLL2, TFIIA, and ALF to orchestrate a wide variety of biological processes.
|
25267403 |
2014 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of MLL1 catalytic function is relevant to mixed-lineage leukemia, and targeting WDR5-MLL1 interaction could be a promising therapeutic strategy for leukemia harboring MLL1 fusion proteins.
|
30626558 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence in situ hybridization demonstrated a rearrangement of the MLL gene and molecular genetic analyses identified a septin family gene, SEPT2, located on chromosome 2q37, as the fusion partner of MLL.
|
16682951 |
2006 |